查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1351092

到 2030 年疱疹性皮肤炎市场预测：按治疗、给药途径、配销通路和地区进行的全球分析

Dermatitis Herpetiformis Market Forecasts to 2030 - Global Analysis By Treatment (Therapeutics, Dietary and Other Treatments), Route of Administration, Distribution channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预测期内全球疱疹性皮肤炎市场的年复合成长率为 9.2%。

疱疹性皮肤炎是一种慢性自体免疫疾病，其特征是剧烈搔痒和灼热感，导致皮肤出现皮疹。它经常发生在患有麸质敏感性肠病或乳糜泻的患者中，乳糜泻是一种麸质消化障碍。从流行病学角度来看，这是一种罕见疾病，主要罹患年轻人。最终的治疗方法是严格的无麸质饮食，可以在几个月内改善皮肤，但无麸质饮食可能需要几年的时间才能成为唯一的治疗方法。

据 DermNet NZ 称，它可能影响 15 岁至 40 岁之间的患者。男性比女性更容易罹患。

疱疹性皮肤炎增加

疱疹性皮肤炎伴随剧烈搔痒。这是一种长期的自体免疫疾病，会导致严重搔痒、潮热和皮疹。患有乳糜泻、麸质敏感肠病和麸质消化问题的人更有可能患上这种疾病。流行病学表明，这是一种罕见疾病，主要影响年轻人。同样，由于寻找疱疹性皮肤炎治疗方法的投资增加，预计市场将快速成长。

与治疗相关的併发症

然而，患者可能会遇到牙齿问题。此外，疱疹性皮肤炎可能被误认为是疥疮。由于药物治疗，患者还患有贫血、骨质疏鬆症、1 型糖尿病和甲状腺问题。儘管有些问题很少见，但它们也会引起神经症状，例如共济失调和神经病变。使用氨苯砜的负面影响，例如血红蛋白减少，可能导致喉咙痛、昏厥、头晕，甚至某些人的肝臟病变，是限制市场扩张的另一个原因。

有利的赎回程序

新兴市场皮肤炎罹患率的增加和有利的报销政策预计也将促进市场成长率。此外，配合措施为提供更好、更经济的治疗方法以及提高对该疾病治疗方案的认识而采取的倡议预计也将影响全球市场。

高成本

这个市场受到高昂的治疗费用的严重限制。患者可能会承受长期照护费用的负担，包括处方药物和健康检查，这可能会阻止他们获得最佳的治疗选择。此外，预计该行业将受到通用治疗方案的出现和严格的法规限制的重大影响。

COVID-19 的影响：

冠状病毒危机以及随后世界多个国家的封锁对领先的尿素循环障碍治疗公司产生了财务影响。此外，私人医疗保健部门是受疫情影响最严重的领域之一。疫情对全球研发、生产和药品供应市场产生了负面影响。此外，由于一些国家政府关门，疫情影响了全球各企业的製药业扩张。

在预测期内，外用药物领域预计将是最大的。

预计外用药物细分市场将成为预测期内最大的细分市场。外用处方药通常是疱疹性皮肤炎的第一线治疗方法。这些药物有乳液、霜剂、栓剂等形式。这种即时预计将导致快速收购和大量行动保留，从而推动细分市场的成长。

预计零售药局领域在预测期内年复合成长率最高

零售药房领域预计在预测期内年复合成长率最高。治疗疱疹性皮肤炎的药物通常可以在零售药局以非专利药的形式购买。零售药局也提供便利的服务，例如家庭药物递送和取得各种药物。此外，由于忙碌的生活方式和紧张的工作日程，消费者对快速获取产品的需求预计将推动脂质调节剂市场的扩张。

比最大的地区

由于遗传疾病和基因突变相关疾病的增加，预计北美在预测期内将占据最大的市场份额。这主要是由于异位性皮肤炎患病不断上升、患者群体的治疗意识较高以及异位性皮肤炎行业的进步。此外，製药公司加大开发新药配合措施、技术进步和高采用率也正在帮助患者做出更好的治疗选择。

复合年复合成长率最高的地区：

由于患者意识较低，亚太地区预计在预测期内将维持最高的年复合成长率。这是由于快速发展的医疗技术、大量的患者以及不断上涨的医疗成本。由于各国研发项目的增加、医疗基础设施的发展、对先进技术外科手术的接受度不断提高以及政府倡议的不断增加，预计市场在预测期内将呈现增长。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球疱疹性皮肤炎市场：依治疗分类

  • 治疗
    • 局部皮质类固醇
    • 磺胺类药物
    • 氨苯砜
  • 用餐
    • 即食食品
    • 烘焙食品
    • 义大利麵
  • 其他治疗

第6章全球疱疹性皮肤炎市场：依给药途径

  • 外用
  • 口服

第7章全球疱疹性皮肤炎市场：按配销通路

  • 零售店
  • 电子商务
  • 药局
  • 其他配销通路

第8章全球疱疹性皮肤炎市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Allergan
  • 3B scientific
  • Acros Organics
  • Aidance Scientific
  • AlliChem
  • Aidance Scientific
  • Canyon Bakehouse
  • GlaxoSmithKline Pharmaceuticals Ltd.
  • HBC Chem
  • Ivy Fine chemicals
  • Nostrum Laboratories Inc.
  • Pfizer Inc.
  • Shingles Skincare
  • AbbVie Inc.
  • Waterstone Technology
Product Code: SMRC23779

According to Stratistics MRC, the Global Dermatitis Herpetiformis Market is growing at a CAGR of 9.2% during the forecast period. Dermatitis Herpetiformis is a chronic autoimmune illness marked by strong itching and burning sensations, resulting in a skin rash. People with celiac disease, a gluten-sensitive enteropathy or anomaly in gluten digestion, frequently have it. Epidemiologically speaking, it is a rare disease that primarily affects young adults. The final course of treatment entails a strict gluten-free diet, with which skin improvement is anticipated in a few months, though it might take years for the gluten-free diet to be the only course of treatment.

According to the DermNet NZ organisation, Patients between the ages of 15 and 40 may be affected. Males are more susceptible to the condition than females.

Market Dynamics:

Driver:

Increasing incidence of dermatitis herpetiformis

Patients with dermatitis herpetiformis have severe itching. It is a long-term autoimmune condition that results in intense itchiness, burning, and skin rashes. People with celiac disease, gluten-sensitive enteropathy, or issues with gluten digestion are more likely to experience it. It is a rare disease that mostly affects young adults, according to epidemiology. Again, due to increasing investments in finding treatments for dermatitis herpetiformis, the market is expected to grow rapidly.

Restraint:

Complications associated with treatment

Patients could, however, experience dental issues. Additionally, it's possible that dermatitis herpetiformis will be mistaken for scabies. Due to therapeutic medications, the patient also suffers anemia, osteoporosis, Type 1 diabetes, and thyroid issues. Although some of the problems are uncommon, there is a potential that they could result in neurological conditions including ataxia and neuropathy. The negative consequences of dapsone use, such as a drop in hemoglobin, which can cause sore throats, fainting spells, dizziness, and even liver problems in some people, are another reason that can limit market expansion.

Opportunity:

Advantageous reimbursement procedures

The increasing incidence of dermatitis and the favorable reimbursement policies in developing nations are also anticipated to contribute to the market growth rate. Additionally, it is anticipated that increased government efforts to provide better and more economical care as well as increased awareness of the disease's treatment options will have an impact on the global market.

Threat:

High cost

The market is severely constrained by the treatment's high cost. Patients may be burdened by the costs of long-term care, which may include prescription drugs and wellness visits, and this may prevent them from accessing the best possible treatment options. Furthermore, it is projected that the industry will be significantly impacted by the advent of generic treatment options and strict regulatory constraints.

COVID-19 Impact:

The corona virus crisis and subsequent lockdown in several nations worldwide have financially impacted major urea cycle disorders treatment firms. Moreover, the private healthcare sector is one of the areas that the pandemic has damaged the most. The pandemic has had a detrimental impact on the worldwide market regarding research and development, production, and pharmaceutical supply. In addition, due to government lockdowns in some countries, the pandemic has impacted the expansion of pharmaceutical industries of various corporations worldwide.

The topical segment is expected to be the largest during the forecast period

The topical segment is expected to be the largest during the forecast period. A topical prescription drug is usually the first line of treatment for dermatitis herpetiformis. These can be in the shape of lotions, creams, suppositories, and other things. Such immediacy leads to speedy acquisition and substantial behaviour maintenance, which is expected to drive segment growth in the market.

The retail pharmacies segment is expected to have the highest CAGR during the forecast period

The retail pharmacies segment is expected to have the highest CAGR during the forecast period. Medication for dermatitis herpetiformis is commonly available as a generic pharmaceutical in retail pharmacies. In addition, retail pharmacies provide convenient services such as medicine delivery to your home and the availability of a wide range of drugs and medicines. Furthermore, lipid-regulating medicines market expansion is expected to be boosted by consumer demand for quick availability of products due to busy lifestyles and stressful work schedules.

Region with largest share:

North America is projected to hold the largest market share during the forecast period, owing to increased inherited and genetic mutation related disorders. This is primarily attributed to increasing prevalence of atopic dermatitis, high treatment awareness among the patient population, and advancement in atopic dermatitis industry. The increasing initiatives taken by the pharmaceutical organizations to generate novel drugs, technological advancements and high adoption rate, which will help patients opt for better treatment.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period, due to the low awareness among patients. This is attributed to strong presence of rapidly developing healthcare technology, huge patient population and rise in healthcare expenditure. With the rise in R&D projects in countries, developing medical infrastructure, rise in acceptance of technologically advanced surgical procedures and rising government initiatives, the market is expected to witness growth over forecast period.

Key players in the market:

Some of the key players in Dermatitis Herpetiformis market include: Allergan, 3B scientific, Acros Organics, Aidance Scientific, AlliChem, Aidance Scientific, Canyon Bakehouse, GlaxoSmithKline Pharmaceuticals Ltd., HBC Chem, Ivy Fine chemicals, Nostrum Laboratories Inc., Pfizer Inc., Shingles Skincare, AbbVie Inc. and Waterstone Technology.

Key Developments:

In May 2023, AbbVie's aesthetics unit is growing its product catalog once again with a new FDA approval. The product, called Skinvive, nabbed an FDA nod this week and falls within Allergan's Juvederm dermal filler collection.

In May 2022, Sidekick and Pfizer launch digital therapeutics solution for Atopic Dermatitis. The solution will be rolled-out in the UK first, followed by Belgium, Norway, the Netherlands, Sweden, France, Ireland, and Japan.

In January 2022, AbbVie Inc. announced that the US FDA has approved RINVOQ (upadacitinib) for the treatment of severe atopic dermatitis in children and adults 12 years of age and older. RINVOQ is recommended for patients who have not responded to previous injection or tablet treatments.

Treatments Covered:

  • Therapeutics
  • Dietary
  • Other Treatments

Route of Administrations Covered:

  • Topical
  • Oral

Distribution channels Covered:

  • Retail stores
  • E-Commerce
  • Pharmacies
  • Other Distribution channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dermatitis Herpetiformis Market, By Treatment

  • 5.1 Introduction
  • 5.2 Therapeutics
    • 5.2.1 Topical Corticosteroids
    • 5.2.2 Sulfa Drugs
    • 5.2.3 Dapsone
  • 5.3 Dietary
    • 5.3.1 Ready-to-eat Meals
    • 5.3.2 Bakery Products
    • 5.3.3 Pasta
  • 5.4 Other Treatments

6 Global Dermatitis Herpetiformis Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral

7 Global Dermatitis Herpetiformis Market, By Distribution channel

  • 7.1 Introduction
  • 7.2 Retail stores
  • 7.3 E-Commerce
  • 7.4 Pharmacies
  • 7.5 Other Distribution channels

8 Global Dermatitis Herpetiformis Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Allergan
  • 10.2 3B scientific
  • 10.3 Acros Organics
  • 10.4 Aidance Scientific
  • 10.5 AlliChem
  • 10.6 Aidance Scientific
  • 10.7 Canyon Bakehouse
  • 10.8 GlaxoSmithKline Pharmaceuticals Ltd.
  • 10.9 HBC Chem
  • 10.10 Ivy Fine chemicals
  • 10.11 Nostrum Laboratories Inc.
  • 10.12 Pfizer Inc.
  • 10.13 Shingles Skincare
  • 10.14 AbbVie Inc.
  • 10.15 Waterstone Technology

List of Tables

  • Table 1 Global Dermatitis Herpetiformis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 3 Global Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 4 Global Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 6 Global Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 7 Global Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 8 Global Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 9 Global Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 10 Global Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 11 Global Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 12 Global Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 13 Global Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 14 Global Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 15 Global Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 16 Global Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 17 Global Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 18 Global Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 19 Global Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 20 North America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 21 North America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 22 North America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 23 North America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 24 North America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 25 North America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 26 North America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 27 North America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 28 North America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 29 North America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 30 North America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 31 North America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 32 North America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 33 North America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 34 North America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 35 North America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 36 North America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 37 North America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 38 North America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 39 Europe Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 40 Europe Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 41 Europe Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 42 Europe Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 43 Europe Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 44 Europe Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 45 Europe Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 46 Europe Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 47 Europe Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 48 Europe Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 49 Europe Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 50 Europe Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 51 Europe Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 52 Europe Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 53 Europe Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 54 Europe Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 55 Europe Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 56 Europe Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 57 Europe Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 58 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 59 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 60 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 61 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 62 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 63 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 64 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 65 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 66 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 67 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 68 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 69 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 70 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 71 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 72 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 73 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 74 Asia Pacific Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 75 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 76 Asia Pacific Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 77 South America Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 78 South America Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 79 South America Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 80 South America Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 81 South America Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 82 South America Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 83 South America Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 84 South America Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 85 South America Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 86 South America Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 87 South America Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 88 South America Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 South America Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 90 South America Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 91 South America Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 92 South America Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 93 South America Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 94 South America Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 95 South America Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)
  • Table 96 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Country (2021-2030) ($MN)
  • Table 97 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 98 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 99 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical Corticosteroids (2021-2030) ($MN)
  • Table 100 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Sulfa Drugs (2021-2030) ($MN)
  • Table 101 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dapsone (2021-2030) ($MN)
  • Table 102 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Dietary (2021-2030) ($MN)
  • Table 103 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Ready-to-eat Meals (2021-2030) ($MN)
  • Table 104 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Bakery Products (2021-2030) ($MN)
  • Table 105 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pasta (2021-2030) ($MN)
  • Table 106 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 107 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 108 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Topical (2021-2030) ($MN)
  • Table 109 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 110 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Distribution channel (2021-2030) ($MN)
  • Table 111 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Retail stores (2021-2030) ($MN)
  • Table 112 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By E-Commerce (2021-2030) ($MN)
  • Table 113 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Pharmacies (2021-2030) ($MN)
  • Table 114 Middle East & Africa Dermatitis Herpetiformis Market Outlook, By Other Distribution channels (2021-2030) ($MN)